v3.21.1
Segment Information
 3 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
Segment Information Segment InformationAbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.The following table details AbbVie’s worldwide net revenues:
Three months ended
March 31,
(in millions)
20212020
Immunology
HumiraUnited States$3,907 $3,656 
International960 1,047 
Total$4,867 $4,703 
SkyriziUnited States$481 $266 
International93 34 
Total$574 $300 
RinvoqUnited States$245 $82 
International58 4 
Total$303 $86 
Hematologic Oncology
ImbruvicaUnited States$999 $966 
Collaboration revenues269 266 
Total$1,268 $1,232 
VenclextaUnited States$225 $201 
International180 116 
Total$405 $317 
Aesthetics
Botox Cosmetic (a)
United States$305 $— 
International172 — 
Total$477 $— 
Juvederm Collection (a)
United States$123 $— 
International198 — 
Total$321 $— 
Other Aesthetics (a)
United States$300 $— 
International43 — 
Total$343 $— 
Neuroscience
Botox Therapeutic (a)
United States$429 $— 
International103 — 
Total$532 $— 
Vraylar (a)
United States$346 $— 
DuodopaUnited States$25 $25 
International104 99 
Total$129 $124 
Ubrelvy (a)
United States$81 $— 
Other Neuroscience (a)
United States$156 $— 
International4 — 
Total$160 $— 
Three months ended
March 31,
(in millions)
20212020
Eye Care
Lumigan/Ganfort (a)
United States$66 $— 
International77 — 
Total$143 $— 
Alphagan/Combigan(a)
United States$80 $— 
International38 — 
Total$118 $— 
Restasis (a)
United States$267 $— 
International13 — 
Total$280 $— 
Other Eye Care (a)
United States$117 $— 
International159 — 
Total$276 $— 
Women's Health
Lo Loestrin (a)
United States$102 $— 
International2 — 
Total$104 $— 
Orilissa/OriahnnUnited States$29 $30 
International1 1 
Total$30 $31 
Other Women's Health (a)
United States
$46 $— 
International— — 
Total$46 $— 
Other Key Products
MavyretUnited States$170 $234 
International245 325 
Total$415 $559 
CreonUnited States$274 $276 
LupronUnited States$171 $195 
International42 38 
Total$213 $233 
Linzess/Constella (a)
United States$215 $— 
International7 — 
Total$222 $— 
SynthroidUnited States$191 $205 
All other (a)
$892 $553 
Total net revenues$13,010 $8,619 
(a) Net revenues include Allergan product revenues after the acquisition closing date of May 8, 2020.